Humulin S (Soluble)

Humulin S is a soluble insulin human injection solution marketed in the European Union. It contains the active ingredient insulin human, a short‑acting analogue of endogenous insulin, supplied as a sterile liquid for subcutaneous administration. The product is prescription‑only and is used to replace or supplement natural insulin in patients with diabetes mellitus. Its formulation enables rapid absorption after injection to control post‑prandial glucose levels.

Humulin S is indicated for the management of blood glucose in adults and children with diabetes.

- Type 1 diabetes mellitus, as part of a basal‑bolus insulin regimen. - Type 2 diabetes mellitus, when oral agents are insufficient to achieve glycemic targets. - Rapid correction of hyperglycemia in acute care or hospital settings under physician direction. - Use in combination with longer‑acting insulin analogues for flexible dosing schedules. - Adjustments during pregnancy or lactation when insulin therapy is required.

Adverse reactions to Humulin S may vary in frequency and severity.

Common: - Low blood sugar (hypoglycemia) symptoms such as sweating, tremor, confusion. - Redness, swelling, or itching at the injection site. - Small lumps of fatty tissue (lipohypertrophy) under the skin. - Unintended weight gain. - Mild nausea or abdominal discomfort. - Transient headache. - Increased appetite.

Serious: - Severe hypoglycemia leading to loss of consciousness or seizures. - Allergic reactions including hives, angioedema, or anaphylactic shock. - Persistent low potassium levels (hypokalemia) that may affect heart rhythm. - Fluid retention causing peripheral edema. - Severe allergic reaction may cause respiratory distress. - Unexplained bruising or bleeding due to platelet dysfunction.

When prescribing Humulin S, clinicians should consider several precautionary factors to ensure safe use.

- Assess hypoglycemia risk in patients with irregular meals or increased physical activity. - Adjust dose in renal or hepatic impairment. - Use with caution in patients with cardiovascular disease. - Monitor pregnant or breastfeeding women closely; insulin requirements may change. - Avoid use in patients with known hypersensitivity to human insulin or excipients. - Rotate injection sites to reduce risk of lipodystrophy. - Review concomitant medications that affect glucose metabolism.

Humulin S can interact with other agents that influence blood glucose or insulin action.

Avoid: - Concurrent use of other rapid‑acting insulins without dose adjustment. - Combination with sulfonylureas in patients prone to severe hypoglycemia. - Use with beta‑blockers that mask hypoglycemia symptoms.

Use with caution: - Corticosteroids may increase insulin requirements. - Thiazide diuretics can raise blood glucose levels. - ACE inhibitors may potentiate insulin’s hypoglycemic effect. - Alcohol consumption can cause unpredictable glucose fluctuations.